Renasight™ Genetic Kidney Panel
Genetic test analyzing 300+ genes linked to kidney disease, helping identify inherited causes of CKD, nephrolithiasis, and related renal conditions.
Accessed through the Renasight™ Sponsored Testing Program•Sponsored by Vertex Pharmaceuticals•Performed by Natera
Designed to support clinical decision-making and ordering in your practice.
For healthcare providers
Overview
The Vertex-sponsored Renasight program enables early identification of APOL1 variants associated with APOL1-mediated kidney disease in a population where genetic drivers of renal decline are frequently underrecognized. Results can inform differential diagnosis, guide clinical management, and clarify whether a genetic etiology underlies progressive CKD. Testing is performed by Natera and fully funded by Vertex Pharmaceuticals, with no cost passed to the patient or practice.
When to consider this test
Patient selection
- Providers may order sponsored testing for patients who meet all of the following:
- Patient self-identifies as African American, African, or Afro-Caribbean
- Patient has a confirmed diagnosis of non-diabetic CKD
- Patient has not undergone dialysis or kidney transplantation
Workflow
How to use this program
- 1
Discuss Eligibility
Review program criteria with patients who may benefit and confirm they meet all eligibility requirements. Obtain informed consent before proceeding.
- 2
Order Test
Submit the Renasight™ requisition and attestation forms (both required). Collect a blood or buccal specimen using a Renasight™ kit, and return it using the prepaid label.
- 3
Review Results
Access results in ~3 weeks and incorporate findings—including APOL1 risk status—into the patient’s diagnostic assessment and care plan.
Billing overview
Program billing
For eligible patients, the sponsor has arrangements with the laboratory that may reduce or cover some or all of the patient's out-of-pocket cost. Actual cost and patient responsibility vary by program criteria. Refer to lab or sponsor materials for details.
Quality & privacy
Laboratory quality & data handling
Testing is performed by Natera, a CLIA-certified laboratory (CLIA 05D1082992) and College of American Pathologists (CAP) certified laboratory (CAP 8737934). Your sample is processed using validated methods and quality controls to support reliable genetic results.
Your health information is handled under privacy and security practices that are intended to align with applicable regulations. For program- and lab-specific details, review the privacy information provided by the laboratory and sponsor.
FAQ
Frequently asked questions
Which CKD patients are appropriate for Vertex-sponsored Renasight APOL1 genetic testing?
The Vertex-sponsored Renasight program is designed for patients of African ancestry who have been diagnosed with non-diabetic chronic kidney disease and who meet the program's eligibility criteria. Patients must self-identify as African American, African, or Afro-Caribbean. Those with a history of dialysis or kidney transplant are not eligible for the sponsored program.
What does the Renasight test evaluate in the sponsored CKD program?
The Renasight test identifies APOL1 risk variants associated with APOL1-mediated kidney disease (AMKD). Results can be integrated with clinical findings to support a more precise etiologic diagnosis and inform management decisions. A diagnosis of AMKD requires clinician interpretation in the context of the patient's full clinical picture.
Is there any cost or obligation associated with ordering Renasight sponsored testing?
There is no cost to the patient or the ordering practice. Vertex Pharmaceuticals fully sponsors the Renasight testing through this program, so patients will not be billed. Ordering the test carries no purchase or prescribing obligation of any kind.
How do I order Renasight genetic testing through the Vertex-sponsored CKD program?
Renasight sponsored testing requires a physician order. Natera provides kit ordering and portal access for clinicians. You can request a test kit through Natera's ordering channels and confirm that your patient meets the program's eligibility criteria. Genetic information sessions are also available through Natera to support patient counseling needs.
Is genetic counseling support available for the Renasight sponsored APOL1 testing program?
Natera offers genetic information sessions that clinicians can leverage for patient support before or after testing. These sessions can help patients understand the implications of their APOL1 results and facilitate informed clinical discussions. This resource is available at no additional cost as part of the sponsored program.
Which patients are eligible for Renasight Chronic Kidney Disease genetic testing?
Patients may qualify for Renasight if they meet the program's eligibility criteria:
- Providers may order sponsored testing for patients who meet all of the following:
- Patient self-identifies as African American, African, or Afro-Caribbean
- Patient has a confirmed diagnosis of non-diabetic CKD
- Patient has not undergone dialysis or kidney transplantation
See an issue with this program?